Vaccinating the World Against Covid-19 Can Take a Lesson From Polio, Smallpox - Bloomberg

Vaccinating the World Against Covid-19 Can Take a Lesson From Polio, Smallpox - Bloomberg

Vaccinating the World Against Covid-19 Can Take a Lesson From Polio, Smallpox - Bloomberg

Posted: 27 Feb 2021 12:00 AM PST

Carol Ferguson: Vaccines work -- life lessons from polio survivors - TribLIVE

Posted: 11 Mar 2021 12:00 AM PST

We've been here before.

For half of the 20th century, polio was affecting tens of thousands of children annually. Transmitted by person-to-person contact, polio's lingering paralytic effects frightened anxious parents so much that people avoided gatherings altogether. Schools were closed, activities were paused. There was no vaccine, no cure, no hope for eradication. The children who were infected were ostracized in their community for fear of further spreading the disease.

Compare that to today.

Over the last year we have seen photos of lonely, frightened covid-19 patients looking out hospital windows. We have heard time and time again that the virus can spread even when the infected person has minimal or no symptoms. We have learned hospitals could be overwhelmed, forced to turn away those who need medical help. And yet, even though we have an effective solution many people are still "vaccine-hesitant."

According to a recent CBS News Poll, nearly 50% of those surveyed said they are "on the fence" or will not get the covid-19 vaccine. Even worse, when asked why, 1 in 5 respondents say they have never gotten any vaccines.

It's this vaccine skepticism that brings sadness to a generation of polio survivors, who are living with the lifelong effects of what is now a vaccine-preventable disease. These effects known as Post-Polio Syndrome (PPS) inspired me to form the Pennsylvania Polio Survivors Network (PPSN). A polio survivor myself, I am a living reminder of what a world without a vaccine looks like. The late effects of polio have put me in a leg brace; I require a cane for stability; I struggle to manage chronic pain and am dependent on a wheelchair for any distance walking. All because the now widely distributed vaccine came too late for me.

Unfortunately, we are now hearing the word "long haulers" being associated with the potential long-term effects (for both children and adults) in those who recover from covid-19. Only history will be able to tell our health care professionals the truth as to what damage this virus is leaving in its path of destruction.

At PPSN, our message on disease prevention is simple, positive and evidence-based: Vaccines work. Early data suggests the covid-19 vaccine is no different.

As of February, nearly 84% of Israel's population 70 and older had received both shots of Pfizer's covid-19 vaccine. These mass vaccinations alone have led to a dramatic drop in cases in those most vulnerable to the disease. Even more encouraging, clinical trials have found the Pfizer-BioNTech vaccine to be 95% effective in preventing covid-19, and both Pfizer and Moderna's shots are successful in lessening the severity of covid-19 cases.

We live in an age where it's far too easy to be guided by misinformation and fear. Speaking not just for myself, but for the thousands of permanently disabled polio survivors in our network, we are hopeful that you will not let fear guide your direction. We aim to inspire everyone to educate themselves on the safety and efficacy of the covid-19 vaccine through easily accessed vaccine information resources.

As a result of a worldwide focus on disease prevention and treatment and the importance of vaccination, polio has been eradicated in the United States and nearly every other country in the world.

We are hopeful that history soon will point to the time when covid-19 was announced as eradicated for the same reason.

Why?

Because we've seen what the world looks like without vaccines. And if history tells us anything, we'll see it again.

Carol Ferguson is the founder of the Pennsylvania Polio Survivors Network (PPSN) and a Rotarian. For more information on the late effects of polio and the effectiveness of vaccines, visit papolionetwork.org.

Categories: Featured Commentary | Opinion

Virus Variants Likely Evolved Inside People With Weak Immune Systems - The New York Times

Posted: 15 Mar 2021 12:00 AM PDT

The version of the coronavirus that surfaced in Britain late last year was shocking for many reasons. It came just as vaccines had offered a glimpse of the end of the pandemic, threatening to dash those hopes. It was far more contagious than earlier variants, leading to a swift increase in hospitalizations. And perhaps most surprising to scientists: It had amassed a large constellation of mutations seemingly overnight.

A coronavirus typically gains mutations on a slow-but-steady pace of about two per month. But this variant, called B.1.1.7, had acquired 23 mutations that were not on the virus first identified in China. And 17 of those had developed all at once, sometime after it diverged from its most recent ancestor.

Experts said there's only one good hypothesis for how this happened: At some point the virus must have infected someone with a weak immune system, allowing it to adapt and evolve for months inside the person's body before being transmitted to others. "It appears to be the most likely explanation," said Dr. Ravindra Gupta, a virologist at the University of Cambridge.

If true, the idea has implications for vaccination programs, particularly in countries that have not yet begun to immunize their populations. People with compromised immune systems — such as cancer patients — should be among the first to be vaccinated, said Dr. Adam Lauring, a virologist and infectious disease physician at the University of Michigan. The faster that group is protected, the lower the risk that their bodies turn into incubators for the world's next supercharged mutant.

"We should give the best shot we can, both literally and figuratively, to protect this population," Dr. Lauring said.

That might be complicated, he added. For the same reason that these people don't mount a strong immune response to the virus, vaccines might not work well in them. So they may need to be treated with cocktails of monoclonal antibodies as well, he said.

Like other viruses, the coronavirus collects mutations every time it replicates. The overwhelming majority of those genetic glitches are insignificant and transient. In most people, an active infection lasts only about a week, not long enough for the virus to acquire more than one noteworthy mutation, if any.

Mutations that make the coronavirus more contagious or enable it to dodge the immune system are extremely rare, researchers reported in a study published last week in the journal Science. "But if they do occur, and if they can get transmitted, then it's open season," said Katrina Lythgoe, an evolutionary biologist at the University of Oxford who led the study.

Over a period of months to years, the virus may string together several such mutations. Scientists can observe this slow evolution using a molecular "clock" that captures the changes over time. But in a person with a weak immune system, this timeline can be greatly accelerated.

Multiple studies have shown that in some people who are immunocompromised, the virus can persist for more than eight months, ample time and opportunity to keep evolving.

"If we look at several time points through that course of infection, and we look at the virus population in that patient, we see — every time — different variants popping up with a large turnover rate," said Vincent Munster, a virologist at the National Institute of Allergy and Infectious Diseases who led one of the studies.

If one of these variants that has gained important mutations is transmitted to someone else, it may spread quickly through the population and seem to have emerged out of nowhere — as in the case of the variant that walloped Britain, and perhaps others identified in South Africa and Brazil.

"That's a pretty decent hypothesis that they've come from people with persistent infection," Dr. Lythgoe said of the variants. "By keeping infection rates low, you're going to reduce the number of immunocompromised people who are infected and reduce the chance that they occur."

"Immunocompromised" is a nebulous term encompassing a wide range of conditions — from diabetes and rheumatoid arthritis to leukemia and lymphoma — and experts disagreed on which conditions may lead to variants.

Some say the list should include older people, as well as those who take medications that suppress the immune system and anyone who does not produce a robust set of antibodies.

"We learned from the vaccines that antibodies matter," said Paul Duprex, director of the Center for Vaccine Research at the University of Pittsburgh. "It's very important to keep an eye on people who are immune-suppressed, who don't have fully functional immune systems."

Dr. Lauring said he was most worried about people with blood-related cancers like leukemia, but did not have strong concerns about those taking drugs like Humira or Enbrel, which are used to treat rheumatoid arthritis.

"It's a different kind of immunosuppression that I'm not sure would lead to this, but no one knows for sure," he said.

Some people with weak immune systems have been known to transmit other viruses over long periods, Dr. Lauring noted. One man in England has shed poliovirus for at least 28 years. Others have had persistent infections with norovirus or influenza.

"We've been dealing with this for a long time," he said. "But just like everything with Covid, we're dealing with it on a big scale."

He and the other experts emphasized that regardless of the risks, it is important not to stigmatize or blame people who have compromised immune systems. Instead, they said, the focus should be on limiting their exposure to the virus.

"Let's get the vaccines into people, let's do good distancing, let's do good masking," Dr. Duprex said. "Everything that we can do to stop the virus spreading is really very important."

Comments

Post a Comment

Popular posts from this blog

Roseola vs. measles rash: What is the difference? - Medical News Today

Image
Roseola and measles are two different diseases that present with a high fever and a rash. They are both most commonly seen in childhood, although measles can affect people of any age, and roseola in adults is very rare. While both diseases share similarities, there are distinguishing factors, such as how the symptoms present and the disease progression. Read on to find out the difference between roseola and measles rashes. Roseola, also known as roseola infantum, sixth disease, or exanthema subitum, is a viral infection that typically affects children. The human herpesvirus 6 (HHV-6) or human herpesvirus 7 (HHV-7) causes roseola. The disease is spread through tiny respiratory droplets that people either breathe in or pick up from surfaces they touch. This disease usually presents in children between the ages of 6–12 months . Children who have this disease experience a high fever, followed by a pink or red rash. Roseola is a self-limiting viral illness, meaning it will typically go awa...
Read more

poliomyelitis treatment

Image
poliomyelitis treatment Drug and Device News March 2019 - P&T Community Posted: 04 Mar 2019 10:35 AM PST NEW DRUG APPROVALS Ontruzant, a Herceptin Biosimilar The FDA has approved trastuzumabdttb (Ontruzant, Samsung Bioepis Company, Ltd.) for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Trastuzumabdttb, a HER2/neu receptor antagonist, is the third FDA-approved biosimilar of Herceptin (Genentech). Patients should be selected for therapy based on an FDA-approved companion diagnostic. Trastuzumab-dttb carries a boxed warning about the risks of cardiomyopathy, serious and fatal infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. Ontruzant will be marketed and distributed in the U.S. by Merck. Sources: Samsung Bioepis, January 21, 2019; Ontruzant . prescribing information, January 2019; FDA, January 18, 2019 Vaxelis, a Combination Vaccine T...
Read more

Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association

Image
causes of precapillary pulmonary hypertension :: Article Creator Long-term Oxygen Therapy Improves Exercise Capacity In PH Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42 meters (about 138 feet) over the distances walked at start of the study, "Long-term oxygen therapy in precapillary pulmonary hypertension — SOPHA study," which was published in Scientific Reports. PH is marked by high blood pressure in the pulmonary arteries, the blood vessels that transport blood from the heart to the lungs. Precapillary PH includes PAH, where blood pressure increases due to the narrowing of pulmonary arteries, along with CTEPH, a rare form of p...
Read more